NEUBASE THERAPEUTICS INC's ticker is NBSE and the CUSIP is 64132K102. A total of 53 filers reported holding NEUBASE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $504,500 | -2.7% | 2,727,027 | 0.0% | 0.03% | -25.0% |
Q4 2022 | $518,681 | -51.8% | 2,727,027 | 0.0% | 0.04% | -52.6% |
Q3 2022 | $1,077,000 | -62.4% | 2,727,027 | 0.0% | 0.08% | -65.9% |
Q2 2022 | $2,863,000 | -44.2% | 2,727,027 | 0.0% | 0.22% | -31.6% |
Q1 2022 | $5,127,000 | -33.1% | 2,727,027 | 0.0% | 0.33% | -25.6% |
Q4 2021 | $7,663,000 | -22.2% | 2,727,027 | 0.0% | 0.44% | -33.6% |
Q3 2021 | $9,844,000 | -24.6% | 2,727,027 | 0.0% | 0.66% | -19.5% |
Q2 2021 | $13,062,000 | -12.8% | 2,727,027 | +34.5% | 0.82% | -21.4% |
Q1 2021 | $14,980,000 | +5.7% | 2,027,027 | 0.0% | 1.04% | +22.4% |
Q4 2020 | $14,169,000 | -7.9% | 2,027,027 | 0.0% | 0.85% | -32.2% |
Q3 2020 | $15,386,000 | -7.9% | 2,027,027 | +6.5% | 1.26% | -30.7% |
Q2 2020 | $16,711,000 | +52.6% | 1,903,227 | +23.7% | 1.81% | +16.1% |
Q1 2020 | $10,954,000 | -1.1% | 1,538,462 | 0.0% | 1.56% | +89.9% |
Q4 2019 | $11,077,000 | +44.3% | 1,538,462 | 0.0% | 0.82% | +48.9% |
Q3 2019 | $7,677,000 | – | 1,538,462 | – | 0.55% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CARNEGIE MELLON UNIVERSITY | 939,412 | $371,000 | 0.21% |
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 470,524 | $186,000 | 0.20% |
CM Management, LLC | 450,000 | $178,000 | 0.20% |
Decheng Capital Management III (Cayman), LLC | 1,000,000 | $395,000 | 0.14% |
AIGH Capital Management LLC | 872,023 | $345,000 | 0.11% |
Greenlight Capital | 2,727,027 | $1,077,000 | 0.08% |
Worth Venture Partners, LLC | 212,035 | $84,000 | 0.05% |
PERKINS CAPITAL MANAGEMENT INC | 98,000 | $39,000 | 0.04% |
Sio Capital Management, LLC | 259,441 | $102,000 | 0.03% |
PRELUDE CAPITAL MANAGEMENT, LLC | 311,000 | $123,000 | 0.00% |